X
Xiaoyan Jiang
Researcher at Tongji University
Publications - 209
Citations - 11393
Xiaoyan Jiang is an academic researcher from Tongji University. The author has contributed to research in topics: Myeloid leukemia & Stem cell. The author has an hindex of 40, co-authored 186 publications receiving 10162 citations. Previous affiliations of Xiaoyan Jiang include BC Cancer Agency & Harbin Medical University.
Papers
More filters
Journal ArticleDOI
Frailty transitions and types of death in Chinese older adults: a population-based cohort study.
TL;DR: This large sample of older adults in China supports that frailty is a dynamic process, characterized by frequent types of transitions, and those who remained frail had the highest likelihood of experiencing painful death, which raises concerns about the quality of life in frail populations.
Journal ArticleDOI
Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation
Juliana Valencia-Serna,Hilal Gul-Uludag,Parvin Mahdipoor,Xiaoyan Jiang,Xiaoyan Jiang,Hasan Uludağ +5 more
TL;DR: It is demonstrated that PA-substitutions on low MW polymers could be useful for siRNA delivery in CML cells for therapeutic purposes.
Journal ArticleDOI
Associations of sleep quality and sleep duration with frailty and pre-frailty in an elderly population Rugao longevity and ageing study.
TL;DR: Preliminary evidences are provided that poor sleep quality and prolonged sleep duration were associated with being frailty and pre-frailty in an elderly population aged 70–87 years and the associations need to be validated in other elderly populations.
Journal ArticleDOI
Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells
TL;DR: Dual targeting BCR-ABL and JAK2 activities in CML stem/progenitor cells may consequently lead to more effective disease eradication, especially in patients at high risk of TKI resistance and disease progression.
Journal ArticleDOI
Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo.
Xiaoyan Jiang,Eddy Ng,Calvin K. Yip,Wolfgang Eisterer,Yves Chalandon,Matthew Stuible,Allen C. Eaves,Connie J. Eaves +7 more
TL;DR: Findings provide new evidence that IL-3 production is a rapid, sustained, and biologically relevant consequence of BCR-ABL expression in primitive hematopoietic cells with multilineage leukemogenic activity.